Mutation-Specific Codon Suppression for Aging and Longevity

Mutation-specific Codon Suppression for Aging and Longevity

VITARNA

Gene Therapy

Artan Bio has proposed a novel approach to address genetic and age-related diseases caused by nonsense mutations. These mutations lead to premature protein translation stops, resulting in incomplete and nonfunctional proteins. The solution involves an engineered suppressor system that specifically recognizes these codons and restores normal protein translation.

Owned by

0x452f3…8C80d

Contract:

0x7b66E…5F9C2

Description

Team

Owner

Owner

Owner

Owner

Owner

Organisation

Artan Bio, LLC

Experiment Cost

$91,300.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Price of VITARNA

$0.753

Project Progress

All updates

All categories

Timeline

Activity

Time	Type	$VITARNA	USD	ETH	From

Mutation-specific Codon Suppression for Aging and Longevity

VITARNA

Gene Therapy

Owned by

0x452f3…8C80d

Contract:

0x7b66E…5F9C2

Description

Team

Owner

Owner

Owner

Owner

Owner

Organisation

Artan Bio, LLC

Experiment Cost

$91,300.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Price of VITARNA

$0.753

Project Progress

All updates

All categories

Timeline

Activity

Time	Type	$VITARNA	USD	ETH	From

Rationale

ARTAN-102 has conducted extensive in vitro experiments demonstrating proof-of-mechanism (p53 protein restoration in Calu-6 cells via suppressor tRNA) with dose-response data and reproducible results across multiple CROs. A pilot in vivo mouse study was performed, but in wild-type C57BL/6 mice for safety/biodistribution only — not in a disease-relevant model. No efficacy has been demonstrated in any disease model (no aged mice, progeroid models, tumor models, or patient-derived organoids), which is the key criterion for TRL 3. The project clearly exceeds TRL 1 given substantial wet-lab data but remains at TRL 2 due to the absence of disease-relevant in vivo efficacy data.

Assessment

Low Confidence

RecommendationSUPPLEMENT

Total Score3.70

Overall Assessment

ArtanBio's Artan-102 program scores a 3.70 out of 5.00, reflecting a solid TRL 2 project with meaningful experimental validation but important gaps remaining before advancing to later preclinical stages.

Strengths: The project's strongest performance is in Therapeutic Relevance (4/5, weighted 1.80) and Utility of Candidates (4/5, weighted 0.80). The scientific rationale linking CGA nonsense mutations to aging is well-supported by recent literature, and the in vitro data package is robust — multiple CRO-validated studies demonstrate dose-dependent p53 restoration in a relevant cell model. The systematic candidate selection process (5 vectors → 2 leads → Artan-102 as lead) is methodical and well-documented. The pilot mouse biodistribution data showing expression across 6 tissues is a meaningful early in vivo milestone. Therapeutic Optionality (4/5) is also strong given the platform nature of the codon suppressor approach across multiple disease-relevant genes.

Areas Requiring Attention: Intellectual Property (3/5) and Prospects for Safety (3/5) are the areas needing the most development. While patent filings exist, the lack of detail on scope, claims, and freedom-to-operate analysis is a concern, particularly given the competitive landscape in codon suppression therapeutics. On safety, the pilot mouse study is encouraging but underpowered and too short to draw definitive conclusions; the cytotoxicity observed with non-purified AAV preparations in the VectorBuilder study is a flag that needs resolution before advancing. The absence of NHP safety data and the ongoing fundraise for that study represent a critical gap.

Key Risks to Monitor: (1) The 27-130x expression difference between large-scale and ultra-purified AAV preparations raises manufacturing/formulation questions that could impact the clinical product; (2) No in vivo functional efficacy data exists yet — only biodistribution; (3) The unconventional DeSci/tokenized funding model may present challenges for later-stage institutional fundraising; (4) The aggressive timeline targeting UAE Phase 1 by Q2 2026 appears ambitious given current funding gaps and remaining preclinical work.

Overall Assessment: The project demonstrates strong scientific foundations and a clear lead candidate with emerging preclinical data appropriate for TRL 2. To advance toward TRL 3, the program needs: in vivo efficacy/functional endpoints, expanded safety characterization (including NHP studies), resolution of the purification/expression paradox, and strengthened IP positioning.

Weighted Score

Therapeutic Relevance

Early experimental results strongly support the hypothesis. In vitro data in Calu-6 cells demonstrates clear dose-response for Artan-102 (p53 restoration via codon suppression), confirmed by both Western Blot and qPCR across multiple CRO studies. The pilot in vivo mouse study shows broad biodistribution across 6 tissues (brain, heart, liver, lung, pancreas, kidney) consistent with AAV9 tropism, with liver showing ~350x expression over vehicle. The biological rationale is well-grounded in published literature (Nature Aging 2025, Koch et al.) linking CpG somatic mutations to epigenetic aging clocks. The mechanism — suppressing CGA→UGA nonsense mutations to restore functional proteins (p53, BRCA, ATM, TERT, etc.) — is biologically compelling and addresses a fundamental driver of aging. However, a score of 5 is withheld because: (1) functional protein restoration has not yet been directly demonstrated in vivo (only RNA-level biodistribution shown), (2) no efficacy/phenotypic endpoints have been measured in animal models yet, and (3) the link between suppressing these mutations and reversing aging phenotypes remains theoretical at this stage.

Therapeutic Optionality

Emerging findings suggest strong alternative application potential. The codon suppressor mechanism targeting arginine CGA nonsense mutations is not limited to aging — the same CGA→UGA stop mutations occur across numerous disease-relevant genes (p53, BRCA2, PTEN, ATM, APC, WRN, TERT, PINK1, PRKN, APP, CDKN2A), spanning oncology, neurodegeneration, and rare genetic diseases. The Abu Dhabi regulatory meeting identified premature aging post-chemotherapy as a potential proof-of-concept indication, representing a concrete alternative clinical pathway. AAV9's broad tissue tropism opens multiple organ-specific indications. The platform nature of the tRNA suppressor approach means new pathways (cystic fibrosis, autism, neurological conditions, cancers) have been identified as addressable. Score is not 5 because these alternative applications remain conceptual and no dedicated experimental work has been performed to validate them beyond the p53/Calu-6 model system.

Intellectual Property

Patent filings have been completed as part of the $300K IPT funding round (2024), and IP tokenization via IP-NFT was completed in Q1 2024, demonstrating proactive IP management. The early in vitro and in vivo results (dose-response, biodistribution, multiple vector constructs including clinical-compatible vectors) provide substantive data that could strengthen existing patent filings. However, the score is limited to 3 because: (1) no details are provided on the scope, claims, or jurisdictions of the patent filings; (2) it is unclear whether the patents cover the specific tRNA suppressor sequences, the AAV9 delivery construct, the therapeutic method, or composition of matter; (3) the competitive landscape for codon suppression/readthrough therapeutics is not addressed; (4) the non-exclusive nature of the Syenex VivoCell Platform license suggests potential IP sharing or limitations; and (5) there is no mention of freedom-to-operate analysis relative to existing AAV9 or tRNA suppressor IP held by others (e.g., ReCode Therapeutics, where the CSO was a co-founder).

Utility Of Candidates

Artan-102 has clearly emerged as the lead drug candidate through a systematic screening and down-selection process. From an initial panel of 5 vectors, Vec2 and Vec3 were identified as leads by Western Blot. Subsequent AAV9 encapsulation studies confirmed Artan-102 as superior to Artan-101, with clear dose-response (Mean Relative Expression ~6.8 at MOI=1E+6 vs ~0.1 at NC). The most recent VectorBuilder studies (Aug and Oct 2025) further characterized two clinical-compatible vector constructs (VB250610-1157tpv and VB250610-1162rmu) alongside the original control vector, with confirmed p53 expression by Western Blot. The AAV9 delivery vehicle is well-characterized with FDA-approved precedent (Zolgensma). A Lonza manufacturing contract using the Xcite™ AAV platform is in place, demonstrating a viable path to GMP production. The candidate's viability in achieving therapeutic effects is supported by in vivo biodistribution data showing expression in all 6 target tissues. Score is not 5 because: (1) no in vivo efficacy/functional protein restoration has been demonstrated yet; (2) the purification challenge identified in the VectorBuilder study (large-scale vs. ultra-purified showing 27-130x expression differences) raises manufacturing/formulation questions that need resolution; and (3) optimal dose and route for therapeutic effect in humans remain undefined.

Prospects For Safety

The pilot mouse safety study (n=4/group, single IV dose 1.8x10^12 GC/mouse, 14 days) showed no significant body weight changes and no significant hematology findings (WBC, neutrophils, lymphocytes, monocytes, eosinophils, basophils all normal), which is encouraging. However, the score is limited to 3 because: (1) the study was very small (n=4/group) and short (14 days), insufficient to detect delayed or rare toxicities; (2) no clinical chemistry data results were reported (only mentioned as collected); (3) no histopathology was performed on collected tissues; (4) the VectorBuilder bright-field microscopy data showed more cell debris with non-purified (large-scale) AAV preparations, indicating cytotoxicity concerns from impurities that need to be addressed; (5) AAV9 gene therapy carries known class risks including hepatotoxicity, immunogenicity, and dorsal root ganglion toxicity that have not been evaluated; (6) no immunogenicity assessment (anti-AAV9 antibodies, T-cell responses) was performed; and (7) the NHP non-GLP tox study is still in fundraising stage ($500K needed), meaning no primate safety data exists. The risks are potentially manageable given AAV9's clinical precedent (Zolgensma), but substantial safety characterization work remains.